



E-NEWS UPDATE JULY 2016 EDITION

Acute Pain Guidelines Training Module

In its ongoing efforts to combat prescription drug abuse and save lives, the Governor's Cabinet Opiate Action Team (GCOAT) recently released Guidelines for the Management of Acute Pain Outside of the Emergency Department.

You may have recently received an email from the GCOAT encouraging you to watch a short training module on the new guidelines. While this training is not mandatory, the module is strongly encouraged.

For those who did not receive the email link, you may access the training video by visiting: <http://ohiorxguidelines.com>

Ohio Medical Marijuana Control Program

In early September, HB523 goes into effect, legalizing medical marijuana in Ohio. The State of Ohio Board of Pharmacy is responsible for implementing rules on the registration of medical marijuana patients and the licensure of medical marijuana dispensaries.

The Board is in the process of developing rules to implement this new law, and is committed to keeping the public up-to-date throughout the process. Those who are interested should check back for more information or can [sign up to receive email updates from the Board of Pharmacy](#).

For questions or updates regarding medical marijuana cultivation, processing or laboratory testing, contact the [Ohio Department of Commerce](#).

For information on physicians recommending medical marijuana, contact the [State Medical Board of Ohio](#).

New and Updated Rules – Q1 and Q2 of 2016

The Board has adopted a number of rule changes in the first and second quarter of 2016. To assist licensees in maintaining compliance with these requirements, a complete list of the changes along with implementation dates can be accessed here: www.pharmacy.ohio.gov/2016rules. Some highlights include the following:

- Changes to the Board's Responsible Person (RP) rule (OAC 4729-5-11) including new requirements for wholesalers and reduction in the notification time when there is a change of RP.
- Personal furnishing requirements for prescribers licensed as terminal distributors of dangerous drugs (OAC 4729-5-17).
- A new central fill pharmacy rule (OAC 4729-5-28).
- Updates to the security and control requirements for terminal distributors of dangerous drugs (OAC 4729-9-11).

Roundtable and Law Presentations at University of Toledo

The Board has added additional dates in Northwest Ohio to its schedule of Roundtables and Law Presentations.

For more information on the Roundtables, including registration information, visit: www.pharmacy.ohio.gov/roundtables

For more information on the Law Presentations, including registration information, visit: www.pharmacy.ohio.gov/2016law

Both the Roundtable and Law Presentations qualify for 2 hours (0.2 CEU) of State of Ohio Board of Pharmacy approved jurisprudence continuing education.

Reporting Gabapentin Products to OARRS

Effective December 1, 2016, the following entities are required to submit the specified dispensing, personal furnishing, or wholesale sale information on all products containing gabapentin to the Ohio Automated Rx Reporting System (OARRS):

- All pharmacies located outside this state and licensed as a terminal distributor of dangerous drugs that dispense gabapentin to outpatients residing in this state.
- All pharmacies located within this state and licensed as a terminal distributor of dangerous drugs that dispense gabapentin to all outpatients.
- All wholesalers licensed as a wholesale distributor of dangerous drugs that sell gabapentin at wholesale shall report those drug transactions.
- All pharmacies licensed as a terminal distributor of dangerous drugs that sell gabapentin at wholesale shall report those drug transactions.
- All prescribers, except veterinarians, located within this state that personally furnish gabapentin to outpatients, including samples.

For more information, please visit: www.pharmacy.ohio.gov/gabapentin

State of Ohio Board of Pharmacy | 77 S. High Street, 17th Floor | Columbus, OH 43215-6126